Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.53 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.50 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP1 | P63208 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 3/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818663 | 0.89 | CKS1B (0.58) | GPR119SMARCA2SMARCA4PBRM1CKS1B | |
| SCHEMBL6228319 | 0.86 | GPR119 (0.49) | GPR119SMARCA2SMARCA4PBRM1CKS1B | |
| SCHEMBL6266142 | 0.84 | SMARCA2 (0.49) | GPR119SMARCA2SMARCA4PBRM1CKS1B | |
| SCHEMBL1136833 | 0.82 | MAPT (0.64) | GPR119SMN1; SMN2GAAMEN1CYP2C19 | |
| SCHEMBL615074 | 0.81 | CHRM2 (0.52) | GPR119SMARCA2SMARCA4PBRM1CKS1B | |
| SCHEMBL22957522 | 0.79 | GPR119 (0.48) | GPR119SMARCA2SMARCA4PBRM1CKS1B | |
| SCHEMBL6694173 | 0.78 | IDO1 (0.42) | SMARCA2SMARCA4PBRM1BACE1PDK2 | |
| SCHEMBL3320806 | 0.78 | GRIA1 (0.51) | GPR119CKS1BSKP1SKP2ACHE | |
| SCHEMBL109888 | 0.78 | CKS1B (0.53) | GPR119SMARCA2SMARCA4PBRM1CKS1B | |
| SCHEMBL7981893 | 0.78 | GAA (0.56) | GPR119SMARCA2SMARCA4PBRM1CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592772-A2 | 5HT7 ANTAGONISTS AND INVERSE AGONISTS | Pfizer Products Incorporated (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040229874-A1 | 5HT7 Antagonists and inverse agonists | PFIZER INC. | 2004-11-18 | — | — | US | disclosed |
| US-6803379-B2 | TREATMENT OF VIRAL, BACTERIAL, PARASITIC, PROLIFERATIVE DISEASES, NEURODEGENERATIVE DISEASES, INFLAMMATORY DISEASES, HEAVY METAL POISONING AND IMMUNOGICAL DISEASES WITH THIOPHENE-2-CARBOXYLIC ACID, 2-FUROIC ACID OR DERIVATIVES | POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) | 2004-10-12 | — | — | US | disclosed |
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | FERNANDEZ-POL JOSE A (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004067703-A2 | 5HT7 ANTAGONISTS AND INVERSE AGONISTS | PFIZER PRODUCTS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | ZFX, ZFR, SLC30A6 | GPR119 3337/4885SMARCA2 4022/4885SMARCA4 4339/4885 |
| US-20040229874-A1 | 5HT7 Antagonists and inverse agonists | HTR7, HTR1A, HTR1B | GPR119 133/4885SMARCA2 4569/4885SMARCA4 4431/4885 |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | ZFX, ZFR, SLC30A6 | GPR119 3121/4885SMARCA2 3975/4885SMARCA4 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.